{'fraction_non_alphanumeric': 0.021067415730337078, 'fraction_numerical': 0.0, 'mean_word_length': 5.0423728813559325, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Cancer Groups Give Part B Plan an F.

Change is hard and often unpopular. Change how people get paid, and they will get up in arms in a hurry. The reaction from oncology groups was overwhelmingly negative last month when CMS proposed altering the way it will pay for Medicare Part B drugs administered in physician offices or hospital outpatient clinics. The Association of Community Cancer Centers lambasted the CMS plan for interfering with providers’ ability to “provide critical cancer care services in their communities.” The American Society of Clinical Oncology (ASCO) averred its support of payment reform but accused CMS for “using heavy-handed reimbursement techniques” to manipulate treatment choices.